Clinical Trials Logo

Clinical Trial Summary

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .


Clinical Trial Description

ADG126 is a novel anti-CTLA-4 fully human IgG1 antibody prodrug that is modified with Adagene Safebody technology to control the activation of anti-CTLA4 activity.ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb which is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed from the preclinical studies of ADG126 in combination with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical settings for better patient responses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04645069
Study type Interventional
Source Adagene Inc
Contact Xiaohong She
Phone 4088389296
Email kristine_she@adagene.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 15, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Active, not recruiting NCT04501276 - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients Phase 1
Active, not recruiting NCT04182516 - Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Phase 1
Terminated NCT00996255 - Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Terminated NCT02444793 - A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03526835 - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05718895 - A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Completed NCT03833427 - Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) Phase 1
Recruiting NCT05607498 - First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma Phase 1
Recruiting NCT05405595 - ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02665416 - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors Phase 1
Terminated NCT01092052 - Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Phase 1
Completed NCT05277402 - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05614258 - Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05394168 - A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors Phase 1